Abstract
High-dose melphalan (MEL) with autologous stem cell transplant (SCT) is an effective therapy for systemic light-chain amyloidosis (AL) and a risk-adapted approach to MEL dosing minimizes transplant-related mortality (
BJH
2007
; 139
Leukemia Lymphoma
2000
;37
:245
Disclosures: No relevant conflicts of interest to declare.
Author notes
Corresponding author
2008, The American Society of Hematology
2008
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal